Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has announced the valuation price (KRW 1,221,000) and the reference price determination method for its listing change following corporate spin-off (surviving entity), applicable on November 24, 2025.
📊 [Key Disclosure Details & Financial Figures]
- Company Name: Samsung Biologics (Surviving Entity)
- Reason for Filing: Corporate spin-off
- Effective Date: November 24, 2025
- Share Class & Price Details:
- Common Stock Valuation Price: KRW 1,221,000
- Maximum Order Price Limit: KRW 2,442,000 (200% of valuation price)
- Minimum Order Price Limit: KRW 611,000 (50% of valuation price)
- Reference Price Determination Method: The initial price determined through single-price auction trading based on quotes received from quote acceptance opening until regular market opening within the range of minimum (KRW 611,000) and maximum (KRW 2,442,000) order prices will become the official reference price.
- Trading Method: Same as general stocks, operating within a ±30% price limit band based on the determined reference price.
- Governing Rules: Article 30 of the Enforcement Rules of the KOSPI Market Business Regulations, etc.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verifying the Officially Determined Reference Price on the Effective Date (November 24, 2025)
This disclosure provides notice regarding the valuation price and order price limits used to calculate the reference price for the listing change on November 24, 2025.
Checking the finalized reference price calculated through single-price auction trading prior to market open on the effective date is essential.
Relevant details can be verified in Korea Exchange (KRX) market data feeds and official announcements on November 24, 2025.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
